

MRD 12-15-99	
To the Honorable Commissioner of Pat 10125	15977 and original documents or copy thereof
To the Honorable Commissioner of Pat 1. Submission Type: New Resubmission (Non-Recordation) Document ID# Correction of PTO Error Reel # Frame # Corrective Document Reel # Frame # Data Element in Question : 1. Name of conveying party(ies): 1. Name of Conveying party(ies): 1. Name of Conveying party(ies): 1. Name of Conveying party(ies):	2. Conveyance Type: Assignment Security Agreement License Change of Name Merger Other US. GOVERNMENT (For Use ONLY by U.S. Government Agencies) Departmental File Secret F Total No. of pages of conveyance document including attachments 5. Name and address of receiving party(ies): DuPont Pharmaceuticals Company Chestnut Run Plaza 974 Centre Road
Additional name(s) of conveying party(ies) attached?: Yes No Execution Date: \(^110/13/1999\) \(^29/29/1999\) \(^39/28/1999\)	Wilmington, DE 19805 Additional name(s) & address(es) attached? □ Yes ■ No
5. Application number(s) or patent number(s):	
If this document is being filed together with a new application, the execution date of the application is: A. Patent Application No.(s): 09/335,086 B. Patent No.(s): Docket No.: DM-6967 Additional numbers attached: □ Yes ■ No	
6. Correspondent Name & Address:	7. Total number of applications and patents involved: 1
DAVID H. VANCE E. I. DU PONT DE NEMOURS AND COMPANY LEGAL-PATENTS 1007 MARKET STREET WILMINGTON, DELAWARE 19898	8. Total fee (37 CFR 3.41)
	9. Deposit account number: 04-1928 (Attach duplicate copy of this page if paying by deposit account)
DO NOT USE THIS SPACE	
of the original document. DANA KING	integration is true and correct and any attached copy is a true copy 3 3 9 Date

09335006

Total number of pages comprising cover sheet: One (1)

PATENT ASSIGNMENT

We, the undersigned

Hereby declare that

We are the true and first inventors of an invention entitled NOVEL CYCLIC HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS (and which is identified as Case Number DM-6967) and which is disclosed in an application for Letters Patent in the United States of America.

For valuable consideration, the receipt and adequacy of which is hereby acknowledged and in fulfillment of our preexisting obligation of assignment, we hereby:

- I. Sell, assign, and transfer unto **DuPont Pharmaceuticals Company**, a General Partnership organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Chestnut Run Plaza, 974 Centre Road, Wilmington, Delaware 19805, hereinafter referred to as the assignee, (A). the sole and entire right, and interest in and to: (1) the aforesaid application for Letters Patent, (2) any priority rights derived from the aforesaid application for Letters Patent by virtue of intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, (3) any and all of our inventions, whether joint or sole, disclosed in the aforesaid application for Letters Patent, (4) any and all applications for Letters Patent for any such inventions in any country whatsoever, (5) any and all patents for any such inventions in any country whatsoever; and (B) the sole right to (1) file such applications in its name or ours, (2) file such applications under the aforesaid International Convention or other treaty or understanding, (3) have said patents granted in its name or ours, and (4) enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future; and
- II. Agree, whenever requested, to communicate to said assignee, its successors, assigns, and legal representatives. any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers or instruments necessary or required by said assignee, its successors, assigns and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid said assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

We further authorize our attorney/patent agent to insert below* the application number and filing date of the aforesaid United States application now identified as Case Number. After the same shall have been made known to him/her by the United States Patent Office.

*The application referred to above (Case No. DM-6967) was filed in the United States Patent Office

on June 17, 1999, and was given Application No. This insertion made by me this 3^{19} day of 1999, 1999.

DAVID H. VANCE, Agent

Swott K. Larsen

PATENT REEL: 010510 FRAME: 0393

RECORDED: 12/15/1999